Biosimilars

NJ Assembly committee approves biosimilar substitution bill

NJ Assembly committee approves biosimilar substitution bill

By Zachary Brennan

Under the bill first proposed in 2014, which won unanimous approval last week from a New Jersey Assembly committee, pharmacists would have to notify prescribers within five days of dispensing an interchangeable biosimilar.

European group criticizes proposed WHO, FDA biosimilar naming schemes

European group criticizes proposed WHO, FDA biosimilar naming schemes

By Zachary Brennan

The EBG (European Biosimilars Group), a part of the EGA (European Generic Medicines Association), says that more complex systems for naming biosimilars increases the likelihood that physicians and pharmacists will leave something out and disrupt the tracking...

US CMS releases new info around biosimilar pricing, uptake

US CMS releases new info around biosimilar pricing, uptake

By Zachary Brennan

With the release of four different documents around the pricing and use of biosimilars this week, the US CMS (Centers for Medicare and Medicaid Services) is making clear it will fully encourage states to call on prescribers to use cost-effective biosimilars...

Photo from Schoolhouse Rock

California, Illinois propose biosimilar substitution bills

By Zachary Brennan

More than a year since California saw its previous biosimilar substitution bill vetoed by its governor and more than two years since Illinois tried its hand, both are again looking to become the ninth and tenth states to see new substitution laws.

Hospira launch biosimilar mAb in the EU

Hospira launches first mAb biosimilar in major EU markets

By Zachary Brennan

Hospira, recently acquired by Pfizer, announced Monday the launch of the first biosimilar monoclonal antibody (mAb), Inflectra (infliximab), in major European markets, following the patent expiry of J&J’s Remicade. 

The comments might just be the tip of the iceberg

Amgen, Pfizer weigh in on EMA draft guideline on biosimilars

By Zachary Brennan

Biopharma heavyweights Amgen, Pfizer and a number of other companies offered their unique takes on the biosimilar draft guidance from the EMA, calling for more clarity and some new additions before the final draft takes effect.

Will this be the first of many biosimilars to hit the Indian market?

Ranbaxy launches India’s first Remicade biosimilar

By Zachary Brennan

Ranbaxy Laboratories has launched the monoclonal antibody Infimab, the first Remicade (Infliximab) biosimilar, in India -- which is the first what could be a few home-grown biosimilar launches.